Drugs / Botulinum toxin serotype A
Botulinum toxin serotype A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00241215 | Jun 2003 → Nov 2005 | myofascial pain syndrome, peripheral neuropathy | University of California, Los Angeles | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2026-05-19 | Ipsen | Results Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity ipsen.com ↗ |
| 2026-03-26 | AbbVie | Results Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC) abbvie.com ↗
Real-world and clinical data reinforce onabotulinumtoxinA (BOTOX ® Cosmetic) as a foundation for high patient satisfaction, natural-looking results, and the gateway to multimodal facial aesthetic treatment plans |
| 2026-01-14 | Ipsen | Results New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS ipsen.com ↗
Data presented highlighted the depth and diversity of evidence across multiple movement disorders — including post‑stroke spasticity, cervical dystonia and blepharospasm, adding to the available evidence of Dysport®(abobotulinumtoxinA) in patient care – alongside new indications under evaluation. |
| 2023-01-20 | Galderma R&D | Results IMCAS 2023: Galderma to share latest data demonstrating high aesthetic improvement and patient satisfaction across its innovative portfolio galderma.com ↗
This study shows high patient satisfaction and investigator preference for Alluzience over powder solutions and long duration of effect at six months[ii] |
| 2022-11-07 | AbbVie | Results AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients abbvie.com ↗
AbbVie (NYSE: ABBV) today announced new results from its exploratory NOVA phase 2 dose-ranging study evaluating the efficacy and safety of AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial fibrillation (POAF) in cardiac surgery patients. |
| 2022-05-31 | Galderma R&D | Results Galderma to present extensive new clinical data across its portfolio of neuromodulators, fillers and biostimulators at the IMCAS World Congress 2022 galderma.com ↗
Strong clinical data supporting Alluzience® (abobotulinumtoxinA, ABO), the first liquid, ready-to-use neuromodulator as an effective and well-tolerated treatment for glabellar (frown) lines, with a rapid onset and long duration of action of up to six months |
| 2021-06-11 | Galderma R&D | Regulatory Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe galderma.com ↗
Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. |
| 2021-02-10 | AbbVie | Regulatory BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition abbvie.com ↗ |
| 2021-01-15 | Ipsen | Results TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications ipsen.com ↗
Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport® (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. |
| 2020-07-09 | AbbVie | Regulatory FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity abbvie.com ↗
Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License Application (sBLA) that supports expanded use of BOTOX ® for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy. |
| 2020-06-22 | AbbVie | Regulatory FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity abbvie.com ↗ |
| 2020-05-23 | Ipsen | Results New surveys show over 80% of patients with spasticity and cervical dystonia treated with botulinum toxin-A experience debilitating symptom recurrence ipsen.com ↗
The results show that over 80% of respondents experienced debilitating symptom recurrence, and revealed that a lack of long-lasting symptom control between injections has a profound impact on the personal and professional lives of patients. |
| 2020-01-06 | Ipsen | Regulatory Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy ipsen.com ↗
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a licence update for Dysport® for the symptomatic treatment of focal spasticity of upper limbs in pediatric cerebral palsy patients, two years of age and older. |
All press releases naming this drug 13 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Botulinum toxin serotype A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00241215 ↗ |
| Known as | BoNT-A | “direct injection of botulinum toxin type A (BoNT-A) into trigger points was efficacious for cervicothoracic myofascial pain” PMID 16052120 ↗ Aug 2005 |
| Known as | botulinum toxin type A | “direct injection of botulinum toxin type A (BoNT-A) into trigger points was efficacious for cervicothoracic myofascial pain” PMID 16052120 ↗ Aug 2005 |
| Route | Other | “direct injection of botulinum toxin type A (BoNT-A) into trigger points” PMID 16052120 ↗ Aug 2005 |